During the last session, Akebia Therapeutics Inc (NASDAQ:AKBA)’s traded shares were 4.39 million, with the beta value of the company hitting 0.88. At the end of the trading day, the stock’s price was $1.92, reflecting an intraday loss of -1.54% or -$0.03. The 52-week high for the AKBA share is $2.89, that puts it down -50.52 from that peak though still a striking 58.33% gain since the share price plummeted to a 52-week low of $0.80. The company’s market capitalization is $501.56M, and the average intraday trading volume over the past 10 days was 9.24 million shares, and the average trade volume was 3.40 million shares over the past three months.
Akebia Therapeutics Inc (AKBA) received a consensus recommendation of Buy from analysts. That translates to a mean rating of 1.00. AKBA has a Sell rating from 0 analyst(s) out of 4 analysts who have looked at this stock. 0 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 4 recommend a Buy rating for it. 0 analyst(s) has rated the stock Underweight. Company’s earnings per share (EPS) for the current quarter are expected to be -0.05.
Akebia Therapeutics Inc (NASDAQ:AKBA) trade information
Akebia Therapeutics Inc (AKBA) registered a -1.54% downside in the last session and has traded in the red over the past 5 sessions. The stock plummet -1.54% in intraday trading to $1.92, hitting a weekly high. The stock’s 5-day price performance is -32.39%, and it has moved by 5.49% in 30 days. Based on these gigs, the overall price performance for the year is -11.52%. The short interest in Akebia Therapeutics Inc (NASDAQ:AKBA) is 16.57 million shares and it means that shorts have 5.03 day(s) to cover.
The consensus price target of analysts on Wall Street is $6.5, which implies an increase of 70.46% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $6 and $7 respectively. As a result, AKBA is trading at a discount of -264.58% off the target high and -212.5% off the low.
Akebia Therapeutics Inc (AKBA) estimates and forecasts
In the rating firms’ projections, revenue will increase 20.99% compared to the previous financial year.
As companies strive to predict their financial trajectories, we turn our attention to the forthcoming financial quarter. Here are the insights gathered from industry analysts. Revenue for the current quarter is expected to be 44.38M as predicted by 3 analyst(s). Meanwhile, a consensus of 3 analyst(s) estimates revenue growth to 44.13M by the end of current fiscal year. As per earnings report from last fiscal year’s results, sales for the corresponding quarters totaled 32.61M and 43.65M respectively. In this case, analysts expect current quarter sales to grow by 36.09% and then jump by 1.12% in the coming quarter.
An analysis of the company’s performance over the past 5 years shows that the company’s earnings grew an estimated 32.58%. While earnings are projected to return 33.33% in 2025.
AKBA Dividends
Akebia Therapeutics Inc is due to release its next quarterly earnings on 2025-Mar-12. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
Akebia Therapeutics Inc (NASDAQ:AKBA)’s Major holders
Akebia Therapeutics Inc insiders own 4.21% of total outstanding shares while institutional holders control 27.33%, with the float percentage being 28.53%. BLACKROCK INC. is the largest shareholder of the company, while 154.0 institutions own stock in it. As of 2024-06-30, the company held over 11.64 million shares (or 5.5499% of all shares), a total value of $11.87 million in shares.
The next largest institutional holding, with 9.28 million shares, is of VANGUARD GROUP INC’s that is approximately 4.526% of outstanding shares. At the market price on 2024-06-30, these shares were valued at $9.46 million.
Also, the Mutual Funds coming in first place with the largest holdings of Akebia Therapeutics Inc (AKBA) shares are Vanguard Total Stock Market Index Fund and iShares Russell 2000 ETF . Data provided on Dec 31, 2024 indicates that Vanguard Total Stock Market Index Fund owns about 5.95 shares. This amounts to just over 2.52 percent of the company’s overall shares, with a $11.41 million market value. The same data shows that the other fund manager holds slightly less at 5.76, or about 2.44% of the stock, which is worth about $11.05 million.
